Literature DB >> 28220990

Oxidative stress, serotonergic changes and decreased ultrasonic vocalizations in a mouse model of Smith-Lemli-Opitz syndrome.

N F Sharif1, Z Korade2,3, N A Porter4, F E Harrison5.   

Abstract

Smith-Lemli-Opitz syndrome is an inherited monogenic disorder in which mutations to the 7-dehydrocholesterol (7-DHC) reductase (Dhcr7) gene lead to deficits in cholesterol synthesis. As a result, many patients suffer from gross physiological and neurological deficits. The purpose of this study was to identify a potential abnormal behavioral phenotype in a compound mutant mouse model for Smith-Lemli-Opitz disease (Dhcr7 Δ3-5/T93M ) to further validate the model and to provide potential targets for future therapeutic interventions. We also sought to identify some of the underlying changes in brain function that may be responsible for behavioral differences among groups. The Dhcr7 compound mutant mice were smaller than their single mutant littermates. Both single and compound heterozygous mice made fewer ultrasonic vocalizations when separated from the dam, which may suggest a communication deficit in these animals. Striking increases of the highly oxidizable 7-DHC were observed in the compound mutant mice. 7-Dehydrocholesterol is the precursor to cholesterol and builds up because of decreased function of the mutated Dhcr7 enzyme. Additionally, several differences were noted in the serotonergic system including increased expression of the serotonin transporter and increased uptake of serotonin by isolated synaptosomes. We propose that changes to the oxidative environment during development can have a significant impact on the development of serotonergic function and that this contributes to behavioral differences observed in the mutant mice.
© 2017 John Wiley & Sons Ltd and International Behavioural and Neural Genetics Society.

Entities:  

Keywords:  zzm321990SERTzzm321990; Antioxidant; Dhcr7; Smith-Lemli-Opitz syndrome; development; mouse model; oxysterols; serotonin; ultrasonic vocalizations; vitamin E

Mesh:

Substances:

Year:  2017        PMID: 28220990      PMCID: PMC5495606          DOI: 10.1111/gbb.12376

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  34 in total

Review 1.  Multiple regulators of ultrasonic vocalization in the infant rat.

Authors:  M A Hofer
Journal:  Psychoneuroendocrinology       Date:  1996-02       Impact factor: 4.905

2.  DHCEO accumulation is a critical mediator of pathophysiology in a Smith-Lemli-Opitz syndrome model.

Authors:  Libin Xu; Karoly Mirnics; Aaron B Bowman; Wei Liu; Jennifer Da; Ned A Porter; Zeljka Korade
Journal:  Neurobiol Dis       Date:  2011-12-11       Impact factor: 5.996

3.  Quantification of F2-isoprostanes as a biomarker of oxidative stress.

Authors:  Ginger L Milne; Stephanie C Sanchez; Erik S Musiek; Jason D Morrow
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

4.  The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome.

Authors:  Darryn M Sikora; Kersti Pettit-Kekel; Jennifer Penfield; Louise S Merkens; Robert D Steiner
Journal:  Am J Med Genet A       Date:  2006-07-15       Impact factor: 2.802

5.  Biological activities of 7-dehydrocholesterol-derived oxysterols: implications for Smith-Lemli-Opitz syndrome.

Authors:  Zeljka Korade; Libin Xu; Richard Shelton; Ned A Porter
Journal:  J Lipid Res       Date:  2010-08-11       Impact factor: 5.922

Review 6.  RSH/Smith-Lemli-Opitz syndrome: a multiple congenital anomaly/mental retardation syndrome due to an inborn error of cholesterol biosynthesis.

Authors:  F D Porter
Journal:  Mol Genet Metab       Date:  2000 Sep-Oct       Impact factor: 4.797

7.  Antioxidants and cognitive training interact to affect oxidative stress and memory in APP/PSEN1 mice.

Authors:  F E Harrison; J Allard; R Bixler; C Usoh; L Li; J M May; M P McDonald
Journal:  Nutr Neurosci       Date:  2009-10       Impact factor: 4.994

8.  Elevated oxidative stress and sensorimotor deficits but normal cognition in mice that cannot synthesize ascorbic acid.

Authors:  Fiona E Harrison; Sarah S Yu; Kristen L Van Den Bossche; Liying Li; James M May; Michael P McDonald
Journal:  J Neurochem       Date:  2008-05-07       Impact factor: 5.372

Review 9.  The use of selective serotonin reuptake inhibitors in autism and related disorders.

Authors:  David J Posey; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle
Journal:  J Child Adolesc Psychopharmacol       Date:  2006 Feb-Apr       Impact factor: 2.576

Review 10.  Ultrasonic vocalizations: a tool for behavioural phenotyping of mouse models of neurodevelopmental disorders.

Authors:  Maria Luisa Scattoni; Jacqueline Crawley; Laura Ricceri
Journal:  Neurosci Biobehav Rev       Date:  2008-08-13       Impact factor: 8.989

View more
  4 in total

1.  Desmosterolosis and desmosterol homeostasis in the developing mouse brain.

Authors:  Luke B Allen; Thiago C Genaro-Mattos; Ned A Porter; Károly Mirnics; Zeljka Korade
Journal:  J Inherit Metab Dis       Date:  2019-04-08       Impact factor: 4.982

2.  Mutations in the zebrafish hmgcs1 gene reveal a novel function for isoprenoids during red blood cell development.

Authors:  Jose A Hernandez; Victoria L Castro; Nayeli Reyes-Nava; Laura P Montes; Anita M Quintana
Journal:  Blood Adv       Date:  2019-04-23

3.  Circulating Human Serum Metabolites Derived from the Intake of a Saffron Extract (Safr'InsideTM) Protect Neurons from Oxidative Stress: Consideration for Depressive Disorders.

Authors:  Fabien Wauquier; Line Boutin-Wittrant; Line Pourtau; David Gaudout; Benjamin Moras; Adeline Vignault; Camille Monchaux De Oliveira; Julien Gabaston; Carole Vaysse; Karène Bertrand; Hélène Abrous; Lucile Capuron; Nathalie Castanon; David Vauzour; Véronique Roux; Nicolas Macian; Gisèle Pickering; Yohann Wittrant
Journal:  Nutrients       Date:  2022-04-05       Impact factor: 5.717

Review 4.  Medication effects on developmental sterol biosynthesis.

Authors:  Zeljka Korade; Marija Heffer; Károly Mirnics
Journal:  Mol Psychiatry       Date:  2021-04-05       Impact factor: 15.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.